Does MDwise Cover Prolia?

What Is Prolia and Why Does Coverage Vary?

Prolia is the brand name for denosumab, a fully human monoclonal antibody that inhibits RANK ligand, blocking osteoclast formation and reducing bone resorption. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and later expanded that label to include men with osteoporosis, glucocorticoid-induced bone loss, and bone loss in patients receiving certain cancer hormone therapies. [1]

Coverage varies across Medicaid managed-care plans because each plan negotiates its own formulary and sets its own clinical criteria within the boundaries established by the state Medicaid agency. MDwise operates under contract with the Indiana Family and Social Services Administration (FSSA), so its rules must be consistent with Indiana Medicaid policy, but the plan retains discretion on specific step-therapy and documentation requirements. [2] Prolia's list price is approximately $1,400 per injection, which is why payers impose clinical criteria rather than covering it on demand.

The FREEDOM trial (N=7,808), a key phase 3 study published in the New England Journal of Medicine in 2009, found that denosumab reduced new vertebral fractures by 68%, hip fractures by 40%, and nonvertebral fractures by 20% compared with placebo over 36 months. [3] That evidence base is the clinical justification insurers use when writing coverage criteria.

MDwise Formulary Status for Prolia

MDwise lists Prolia in a specialty drug tier and requires prior authorization (PA) before the plan will pay for it. Without an approved PA, a claim submitted by a physician's office or infusion center will be denied at point of service. Formulary tiers can shift during annual contract renewals, so members should confirm the current tier by calling the MDwise pharmacy or medical benefits line or by reviewing the most recent Evidence of Coverage document posted on the MDwise website.

Indiana Medicaid mandates that managed-care entities maintain a formulary that covers medically necessary services consistent with federal Medicaid law. Under 42 CFR § 438.210, managed-care organizations must have procedures for prior authorization that do not create barriers to medically necessary care. [4] If a drug is not on the MDwise formulary at all, a prescriber can submit a formulary exception request, which MDwise must adjudicate using clinical criteria.

Denosumab is also used at a much higher dose (120 mg monthly) under the brand name Xgeva for oncology indications such as prevention of skeletal-related events in solid tumor bone metastases. MDwise's coverage criteria for Prolia (60 mg) and Xgeva (120 mg) are evaluated separately because the clinical contexts differ substantially.

What Clinical Criteria Does MDwise Use?

MDwise generally follows criteria that mirror the American Association of Clinical Endocrinologists and American College of Endocrinology 2020 clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis, which stratify fracture risk and recommend sequencing of therapy accordingly. [5]

Typical required documentation for a Prolia PA includes:

Bone mineral density (BMD) result. A dual-energy X-ray absorptiometry (DXA) scan showing a T-score at or below -2.5 at the lumbar spine or femoral neck meets the standard osteoporosis threshold. Some plans also approve Prolia at T-scores between -1.0 and -2.5 (osteopenia range) when combined with a fragility fracture history or a high FRAX 10-year major osteoporotic fracture probability. The World Health Organization defines osteoporosis as a T-score at or below -2.5 and osteopenia as a T-score between -1.0 and -2.5. [6]

Step therapy with oral bisphosphonates. MDwise commonly requires documentation that the member tried alendronate (Fosamax) 70 mg weekly or risedronate (Actonel) 35 mg weekly for at least six months and either could not tolerate it, had a contraindication (such as an esophageal motility disorder or inability to remain upright for 30 minutes), or experienced continued bone loss despite adherent use. [7] The rationale is cost-effectiveness: a year of alendronate costs under $150 in generic form, versus roughly $2,800 for two Prolia injections annually.

FRAX score. A 10-year fracture probability of 20% or greater for major osteoporotic fracture, or 3% or greater for hip fracture, as set by the National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation), can support PA approval even in members whose T-scores fall in the osteopenia range. [8]

Prescriber type. Some MDwise prior authorization requests for specialty biologics require attestation from a specialist (endocrinologist, rheumatologist, or geriatrician) rather than a primary care provider, though this requirement is not universal.

How to Submit a Prior Authorization for Prolia Under MDwise

The prescribing provider or their office staff submits the PA request either through MDwise's online provider portal, by fax using the MDwise specialty medication PA form, or through CoverMyMeds, which MDwise accepts for specialty drug requests.

Standard turnaround under Indiana Medicaid managed-care rules is 14 calendar days for non-urgent requests and 72 hours for urgent requests, per 42 CFR § 438.210(d). [4] If a member is hospitalized or facing imminent fracture risk, the provider can request an expedited review.

The PA packet should include: the DXA report with site-specific T-scores, a clinical note documenting the diagnosis (ICD-10 code M81.0 for age-related osteoporosis without pathological fracture is most common), the bisphosphonate trial documentation or reason for contraindication, the FRAX score printout from the WHO Fracture Risk Assessment Tool website, and the prescriber's contact information and NPI.

The FDA label for Prolia specifies that it should not be used in patients with hypocalcemia until the condition is corrected, and that calcium and vitamin D supplementation is required during therapy. [1] Including documentation of baseline calcium and any supplementation plan in the PA packet shows medical appropriateness and may speed approval.

Step Therapy Requirements and Exceptions

Step therapy, sometimes called "fail first" policy, is the main barrier for members who have not previously tried an oral bisphosphonate. MDwise's step therapy requirement for Prolia typically specifies a minimum trial of six months of an oral bisphosphonate. Acceptable step agents generally include alendronate, risedronate, ibandronate (Boniva), or zoledronic acid (Reclast) 5 mg IV annually, though IV zoledronic acid may be considered equivalent to Prolia in cost and route of administration at some plans.

Indiana passed step therapy reform legislation consistent with the model act promoted by the National Alliance of Mental Illness and supported by the Arthritis Foundation. Under Indiana law, exceptions to step therapy must be granted when: the required drug is contraindicated for the member, the required drug is expected to cause an adverse reaction, the member previously tried and failed the required drug, or the required drug is not in the member's best interest based on clinical judgment. [9] A prescriber invoking any of these exceptions must submit supporting documentation with the PA request.

Patients with severe gastroesophageal reflux disease (GERD), Barrett's esophagus, or documented inability to sit upright for at least 30 minutes have a strong clinical basis for bisphosphonate intolerance exceptions. The American Gastroenterological Association has published guidance on the esophageal risks of oral bisphosphonates that can be cited in exception letters. [10]

Patients who have already completed a course of anabolic therapy (teriparatide, abaloparatide, or romosozumab) should move to antiresorptive therapy to preserve gains; Prolia is an accepted option in that clinical sequence per the Bone Health and Osteoporosis Foundation guidelines. [8]

What Happens If MDwise Denies a Prolia Claim?

A denial notice from MDwise must explain the specific reason for denial and must describe the member's appeal rights. Under federal Medicaid managed-care regulations at 42 CFR § 438.408, members have at least 30 days to file a standard internal appeal (grievance) and at least 10 days to request an expedited appeal. [11]

The appeal process has two levels within MDwise and then an external independent review. If all internal appeals are exhausted, the member or provider can request a state fair hearing through the Indiana FSSA Office of Medicaid Policy and Planning. State fair hearings are conducted by an administrative law judge who is independent of MDwise.

Common grounds for overturning a Prolia denial include:

• Documentation that the required oral bisphosphonate caused an adverse event (upper GI symptoms, jaw osteonecrosis with prior dental procedure, atypical femoral fracture on prior therapy).
• A FRAX score that meets or exceeds the 20% major osteoporotic fracture threshold.
• A spine or hip T-score below -3.0, which most guidelines classify as severe osteoporosis and which some plans treat as an automatic approval criterion.
• A second opinion letter from a specialist explicitly explaining why Prolia is the appropriate next step given the member's full clinical picture.

The HealthRX clinical team has reviewed prior authorization denial patterns for Prolia across multiple Medicaid managed-care plans and notes that denial rates drop significantly when PA packets include all three of the following: a dated DXA report with numeric T-scores (not just a physician's description), a printed FRAX calculator output, and a typed bisphosphonate trial summary with specific dates, dosage, and documented adverse effects or lab results. Submitting incomplete packets accounts for most first-round denials that are later reversed on appeal.

Cost Sharing for Prolia Under MDwise Medicaid

Most MDwise members enrolled in standard Medicaid pay little to no cost-sharing for covered drugs, including specialty drugs like Prolia. Indiana Medicaid's nominal cost-sharing rules generally cap member cost-sharing at $4 per prescription for non-preferred drugs for certain populations, and federal law prohibits cost-sharing for many low-income Medicaid beneficiaries. [12]

For members enrolled in MDwise HIP (Healthy Indiana Plan), which is the Medicaid expansion plan for adults aged 19 to 64 with household incomes up to 138% of the federal poverty level, cost-sharing may be slightly higher but is still capped by federal Medicaid rules. The HIP plan uses POWER accounts funded by small member contributions, but specialty biologics approved under PA are generally covered under the plan benefit and do not exhaust the POWER account. [2]

Members who are dually eligible for Medicare and Medicaid (dual-eligible or "dual-duals") would typically have Prolia billed under Medicare Part B rather than MDwise Medicaid, because Prolia is administered by injection in a physician's office or clinical setting and is therefore a medical benefit, not a pharmacy benefit, under Medicare. [13] In that scenario, MDwise Medicaid may cover the Medicare Part B cost-share.

Prolia Administration and Billing Codes for Providers

Prolia is administered as a 60 mg subcutaneous injection every six months, typically in a physician's office, infusion center, or by a nurse practitioner or physician assistant under a collaborative practice agreement. The injection must not be given more frequently than every six months, and patients must supplement with at least 1 to 000 mg of calcium and 400 IU of vitamin D daily unless hypercalcemia is present. [1]

For billing to MDwise as a medical (not pharmacy) benefit, the relevant HCPCS code is J0897 (injection, denosumab, 1 mg), with 60 units representing the 60 mg dose. Providers should verify MDwise's current reimbursement rate and billing requirements before administering the first dose.

Prior authorization is linked to the HCPCS code, the diagnosis code, and the provider NPI. A PA approved for one clinical setting (e.g., the endocrinologist's office) may not automatically transfer to a new provider if the patient changes physicians, so new providers should submit a fresh PA request.

Alternatives If MDwise Will Not Cover Prolia

If MDwise denies Prolia and the denial is upheld after appeal, several alternatives exist:

Generic or brand oral bisphosphonates. Alendronate 70 mg weekly is available as a generic for under $10 per month at many pharmacies and is appropriate for most patients who have not yet tried it. [7]

Zoledronic acid (Reclast) IV annually. This intravenous bisphosphonate is given as a single 5 mg infusion once per year and avoids the GI tolerability issues of oral agents. The Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly (HORIZON) Key Fracture Trial (N=7,765) showed a 70% reduction in morphometric vertebral fractures and a 41% reduction in hip fractures over three years. [14]

Raloxifene (Evista). A selective estrogen receptor modulator approved for osteoporosis prevention and treatment in postmenopausal women. It reduces vertebral fracture risk but has not shown hip fracture risk reduction in randomized trials. [15]

Amgen patient assistance. Amgen, the manufacturer of Prolia, operates the Amgen Safety Net Foundation program, which may provide Prolia at no cost for uninsured or underinsured patients who meet income eligibility criteria. Prescribers can access this program through the Amgen Assist 360 portal.

Manufacturer coupon or copay card. Copay assistance cards from Amgen are primarily designed for commercially insured patients and typically cannot be used by Medicaid members due to federal anti-kickback rules, but the patient assistance program is a separate mechanism that does apply to Medicaid-ineligible gaps.

Monitoring Requirements During Prolia Therapy

Once MDwise approves Prolia and treatment begins, ongoing monitoring is required both clinically and for PA renewal purposes.

A repeat DXA scan is typically performed every one to two years during Prolia therapy to document treatment response. The International Society for Clinical Densitometry recommends DXA monitoring intervals based on clinical indication and baseline T-score. [16]

Serum calcium should be checked before each injection. Prolia can cause hypocalcemia, particularly in patients with renal impairment, vitamin D deficiency, or hypoparathyroidism. The FDA label includes a boxed warning for serious hypocalcemia. [1]

A critical, FDA-acknowledged issue is the rebound vertebral fracture risk that can occur if Prolia is discontinued without transitioning to a bisphosphonate. Multiple vertebral fractures have been reported within 12 to 18 months of stopping denosumab. The 2020 AACE/ACE guidelines state: "After stopping denosumab, an antiresorptive agent such as a bisphosphonate should be prescribed to prevent rapid bone loss and potential rebound vertebral fractures." [5] MDwise PA renewals for Prolia may therefore require documentation of ongoing clinical need, typically an annual or biannual review.

Dental health is another monitoring priority. Osteonecrosis of the jaw (ONJ) is a rare but serious adverse effect associated with denosumab. The FDA label advises a dental examination before starting Prolia and avoidance of invasive dental procedures during treatment when possible. [1] The American Dental Association recommends that patients on bone-modifying agents inform their dentist and that providers consider drug holidays before major dental procedures, though the evidence base for timing of drug holidays is still evolving. [17]

Special Populations: Who Qualifies for Prolia Beyond Postmenopausal Women?

MDwise coverage criteria may extend beyond postmenopausal women with primary osteoporosis. The FDA has approved Prolia for:

• Men with osteoporosis at high fracture risk (approved 2012). [1]
• Glucocorticoid-induced osteoporosis in men and women at high fracture risk who are on systemic glucocorticoids (7.5 mg or more of prednisone equivalent per day for six months or more) (approved 2018). [1]
• Bone loss in men receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer.
• Bone loss in women receiving adjuvant aromatase inhibitor therapy for breast cancer.

The ACR 2022 guideline on glucocorticoid-induced osteoporosis, published in Arthritis and Rheumatology, recommends denosumab as an option for high-risk patients on long-term systemic glucocorticoids when oral bisphosphonates are not suitable. [18] Referencing this guideline in a PA request for a glucocorticoid-induced osteoporosis indication may strengthen the clinical justification.

For male osteoporosis, the ADAMO trial demonstrated that denosumab 60 mg every six months increased lumbar spine BMD by 5.7% over 12 months in men with low bone mass, compared with 0.9% for placebo (P<0.001). [19] This trial data can be used to support PA requests for male members under MDwise.

Members with renal impairment (estimated glomerular filtration rate below 35 mL/min/1.73m2) often cannot use oral bisphosphonates or zoledronic acid safely due to nephrotoxicity risk. For these members, Prolia is clinically appropriate as a first-line agent, and MDwise medical directors reviewing PA requests should recognize the contraindication to alternative therapies as grounds for bypassing step therapy. The National Kidney Foundation's KDIGO guidelines address bone disease management in chronic kidney disease. [20]